Pfizer

BetterInvesting™ Magazine Update on Paychex Inc. and Pfizer Inc.

Retrieved on: 
Thursday, March 28, 2024
Paychex, Committee, PFE, Reddit, PAYX, IPO, CFA, Pfizer, Initial public offering, National Association, Undervalued stock, Security (finance)

Learn more about how to analyze companies and pick the best stocks at:

Key Points: 
  • Learn more about how to analyze companies and pick the best stocks at:
    Check the June/July 2024 issue of BetterInvesting Magazine for more details about the latest stocks.
  • Non-members can utilize the limited, trial version of the BetterInvesting online stock selection and analysis tools to study the investment potential of Paychex Inc. and Pfizer Inc. by viewing their fundamental data and applying judgments.
  • As stated, the BetterInvesting committee's Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors.
  • BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases.

Headlands Research Announces Fifth Research Site under Partnership with Pfizer to Improve Diversity in Clinical Trials

Retrieved on: 
Thursday, March 28, 2024
Research, SCRS, Pfizer, Health equity, Partnership, SAN, Site, Physician, Pharmaceutical industry

SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Headlands Research, a leading multinational network of clinical trial sites, today announced a fifth site, Headlands Research Orlando, as part of its partnership with Pfizer to create multiple clinical trial sites in areas with highly diverse demographics.

Key Points: 
  • "As an organization, we have been committed to diversity in clinical trials since day one," said Kyle Burtnett, CEO of Headlands Research.
  • "Our partnership with Pfizer has been a critical component in our continued goal of making clinical research accessible to all."
  • Headlands Research Orlando is the fifth and final site in the organization's partnership with Pfizer, fulfilling a multi-year commitment.
  • A multi-therapeutic site, Headlands Research Orlando was built from the ground up to improve health equity and representativeness in clinical research.

Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024

Retrieved on: 
Tuesday, March 19, 2024
Editorial, Health, Culture, Climate change, Organization, Biotechnology, Growth, Novo Nordisk, David Berry (inventor), MIC, Pfizer, Thermo Fisher Scientific, Flagship Pioneering, MRNA, AI, Hope, Flagship, Samsung, Investment, Therapy, Most, Ecosystem, Indigo Agriculture, Multimedia, Management

CAMBRIDGE, Mass., March 19, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2024, ranking as the #3 most innovative company in North America. This is the third consecutive year Flagship has been named to the list, moving up two spots since 2023.

Key Points: 
  • CAMBRIDGE, Mass., March 19, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2024, ranking as the #3 most innovative company in North America.
  • This is the third consecutive year Flagship has been named to the list, moving up two spots since 2023.
  • The World's Most Innovative Companies stands as Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year.
  • Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability.

Assess Key Digital Marketing Aetrics of United States pharma Assets in NSCLC, Including Branded Websites for Patients and HCPs, Unbranded Websites, and Social Media

Retrieved on: 
Friday, March 15, 2024
AstraZeneca, Pfizer, Digital, Comparison, Patient, Roche, Social media, Merck, BMS, Lung cancer, DDA, HCP, Pharmaceutical industry

Overall, the highest proportion of traffic to top branded patient NSCLC websites originated from direct and organic sources.

Key Points: 
  • Overall, the highest proportion of traffic to top branded patient NSCLC websites originated from direct and organic sources.
  • Overall, the highest proportion of traffic to branded NSCLC websites for HCPs originated from direct sources, followed by paid and organic traffic.
  • This report assesses key digital marketing metrics of pharma assets in NSCLC, including branded websites for patients and HCPs, Unbranded websites, and social media accounts.
  • Compare top branded and unbranded assets for patients by how they address and support different patient needs.

Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris

Retrieved on: 
Monday, March 11, 2024
Claim, Agreement, Prejudice, Action, Defendant, Summons, Person, Fee, Clerk, Viatris, ARE, Settlement, Counsel, Court of Common Pleas, Pfizer, Court, Hearing, Law, Generic drug

your rights MAY be affected by a class action lawsuit pending in this court.

Key Points: 
  • your rights MAY be affected by a class action lawsuit pending in this court.
  • A hearing will be held on June 12, 2024 at 1:00 p.m. Eastern Time, before the Hon.
  • Please do not contact the Court, the Clerk's office, Viatris, the other Defendants, or their counsel regarding this notice.
  • All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to Lead Counsel or the Claims Administrator.

EQS-News: Press Release: Dr Jean-Yves Parisot assumes CEO position from Dr Heinz-Jürgen Bertram

Retrieved on: 
Wednesday, March 13, 2024
Pfizer, Cosmetics, International Organization (journal), Supervisory board, Nutrition, Veterinary medicine, MBA, Food, Life, Executive Committee, HEC Paris, Drink, Air Liquide, News, Taste, Flavoring, Partnership

- Dr Jean-Yves Parisot, an internationally experienced executive from within the company, takes over

Key Points: 
  • - Dr Jean-Yves Parisot, an internationally experienced executive from within the company, takes over
    Dr Heinz-Jürgen Bertram is handing over the CEO position at Symrise AG to Dr Jean-Yves Parisot.
  • The Supervisory Board also renewed the contract of Dr Jean-Yves Parisot for another four years until the end of September 2028.
  • We are deeply grateful to Heinz-Jürgen Bertram for his achievements.”
    “We are excited that Jean-Yves Parisot, an internationally experienced executive from within the company, will take over as CEO.
  • Dr Heinz-Jürgen Bertram, CEO of Symrise AG: „Today Symrise is an industry leader, combining innovation capability, excellent quality, and sustainability.

BNTX DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

Retrieved on: 
Sunday, March 10, 2024
Titan, Pfizer–BioNTech COVID-19 vaccine, Court, BioNTech, Class, Plaintiff, Pfizer, Risk, Advertising, COVID-19, BNTX

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

BNTX DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX

Retrieved on: 
Monday, March 11, 2024
Titan, Pfizer–BioNTech COVID-19 vaccine, Court, BioNTech, Class, Pfizer, Risk, Advertising, COVID-19, BNTX

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

BIONTECH SE (NASDAQ: BNTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE

Retrieved on: 
Monday, March 11, 2024
Pfizer–BioNTech COVID-19 vaccine, BioNTech, Pfizer, ADS, Cancer, Court, Biotechnology, News, Advertising, Complaint, District court, Risk, COVID-19, BNTX, Infection, Defendant, Security (finance)

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

DEADLINE ALERT for DADA, BNTX, and CMI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, March 11, 2024
Nexus, Pfizer–BioNTech COVID-19 vaccine, Pfizer, Suite, The Company, BioNTech, Investment, Marketing, Risk, COVID-19, Law, Defendant, Security (finance)

LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles